1. Cost-effectiveness analysis of Recovery Management Checkups (RMC) for adults with chronic substance use disorders: evidence from a 4-year randomized trial
- Author
-
Derek M. Freitas, Michael T. French, Michael L. Dennis, Kathryn E. McCollister, Christy K. Scott, and Rodney R. Funk
- Subjects
medicine.medical_specialty ,Cost–benefit analysis ,business.industry ,media_common.quotation_subject ,Medicine (miscellaneous) ,Cost-effectiveness analysis ,Abstinence ,law.invention ,Psychiatry and Mental health ,Long-term care ,Randomized controlled trial ,law ,Intervention (counseling) ,Economic evaluation ,Physical therapy ,Medicine ,Substance use ,business ,Psychiatry ,media_common - Abstract
Aims This study performs the first cost-effectiveness analysis (CEA) of Recovery Management Checkups (RMC) for adults with chronic substance use disorders. Design Cost-effectiveness analysis of a randomized clinical trial of RMC. Participants were assigned randomly to a control condition of outcome monitoring (OM-only) or the experimental condition OM-plus-RMC, with quarterly follow-up for 4 years. Setting Participants were recruited from the largest central intake unit for substance abuse treatment in Chicago, Illinois, USA. Participants A total of 446 participants who were 38 years old on average, 54% male, and predominantly African American (85%). Measurements Data on the quarterly cost per participant come from a previous study of OM and RMC intervention costs. Effectiveness is measured as the number of days of abstinence and number of substance use-related problems. Findings Over the 4-year trial, OM-plus-RMC cost on average $2184 more than OM-only (P
- Published
- 2013